重组人SCF(大肠杆菌表达)

干细胞因子

产品号 #(选择产品)

产品号 #78062_C

干细胞因子

总览

干细胞因子 (SCF) 是一种早期作用的细胞因子,在胚胎和成人造血的调控中起着关键作用。SCF 促进细胞存活、增殖、分化、粘附以及在造血系统多个层面的功能性激活。SCF 与其他细胞因子(例如血小板生成素和 Flt3/Flk-2 配体)一起,常用于促进培养的原始造血干细胞和多能祖细胞的扩增 (Martin et al.; Kent et al.)。SCF 与多种生长因子(包括 IL-2、IL-3、IL-6、IL-7、G-CSF 和促红细胞生成素)协同作用,促进髓系和红系祖细胞以及部分淋巴系祖细胞的增殖和分化 (Broudy)。SCF 也是肥大细胞和嗜酸性粒细胞的主要生长和活化因子。

SCF 有两种生物活性剪接形式:可溶性剪接体和跨膜型剪接体。与其受体(c-Kit 酪氨酸激酶受体;CD117)结合后,SCF 可激活 PI3K、JAK/STAT 和 MAPK 通路。据报道,SCF 和 c-Kit 信号转导在色素沉着、生育力、血管生成、通过 c-Kit 阳性的 Cajal 间质细胞促进肠道运动以及神经干细胞和祖细胞向脑损伤部位迁移方面发挥重要作用。

亚型
细胞因子
 
细胞类型
造血干/祖细胞,中胚层,PSC衍生,多能干细胞
 
种属

 
研究领域
干细胞生物学
 
纯度
≥ 97 %
 

Data Figures

(A) The biological activity of Human Recombinant SCF was tested by its ability to promote the proliferation of TF-1 cells. Cell proliferation was measured after 72 hours of culture using a fluorometric assay method. The EC50 is defined as the effective concentration of the growth factor at which cell proliferation is at 50% of maximum. The EC50 in the above example is 1 ng/mL.
(B) 1 μg of Human Recombinant SCF was resolved with SDS-PAGE under reducing (+) and non-reducing (-) conditions and visualized by Coomassie Blue staining. Human Recombinant SCF has a predicted molecular mass of 18.6 kDa.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
78062.2, 78062.1, 78062
Lot #
1000122636 or higher
Language
English
Catalog #
78062.2, 78062.1, 78062
Lot #
1000122635 or lower
Language
English
Document Type
Safety Data Sheet
Catalog #
78062.2, 78062.1, 78062
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (3)

Publications (1)

Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators. I. Elcheva et al. Nature communications 2014 jul

Abstract

Advancing pluripotent stem cell technologies for modelling haematopoietic stem cell development and blood therapies requires identifying key regulators of haematopoietic commitment from human pluripotent stem cells (hPSCs). Here, by screening the effect of 27 candidate factors, we reveal two groups of transcriptional regulators capable of inducing distinct haematopoietic programs from hPSCs: pan-myeloid (ETV2 and GATA2) and erythro-megakaryocytic (GATA2 and TAL1). In both cases, these transcription factors directly convert hPSCs to endothelium, which subsequently transform into blood cells with pan-myeloid or erythro-megakaryocytic potential. These data demonstrate that two distinct genetic programs regulate the haematopoietic development from hPSCs and that both of these programs specify hPSCs directly to haemogenic endothelial cells. In addition, this study provides a novel method for the efficient induction of blood and endothelial cells from hPSCs via the overexpression of modified mRNA for the selected transcription factors.

更多信息

更多信息
Species Human
Purity ≥ 97%
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。